Quick Answer
Eledon Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2016.
Eledon Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$45.62M -26.1% |
-$36.18M +69.0% |
-$116.54M -32.5% |
-$87.97M -154.9% |
-$34.51M -51.3% |
-$22.81M -42.5% |
| Diluted EPS | -$0.52 +21.2% |
-$0.66 +86.0% |
-$4.73 +23.2% |
-$6.16 -164.4% |
-$2.33 | — |
| Total Assets | $169.01M -4.7% |
$177.41M +99.2% |
$89.07M -4.0% |
$92.79M -45.6% |
$170.55M -13.5% |
$197.19M +1703.9% |
| Cash and Equivalents | $22.81M +11.0% |
$20.55M +345.6% |
$4.61M -91.8% |
$56.41M -33.5% |
$84.83M -25.7% |
$114.19M +1199.0% |
| Stockholders Equity | $81.08M +29.8% |
$62.45M +228.8% |
-$48.49M -157.6% |
$84.18M -48.7% |
$164.00M -14.0% |
$190.60M +1913.7% |
| R&D Expense | $66.27M +27.5% |
$51.96M +71.4% |
$30.31M +11.9% |
$27.08M +14.1% |
$23.73M +287.1% |
$6.13M -24.6% |
| Operating Income | — | — | -$43.00M +51.4% |
-$88.43M -139.9% |
-$36.87M -99.7% |
-$18.46M -15.0% |
| Shares Outstanding | 75.43M +26.2% |
59.79M +146.9% |
24.21M +75.8% |
13.78M -3.7% |
14.31M -5.6% |
15.16M +2004.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2017 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$17.46M | -122.7% | -55.7% |
| Diluted EPS | September 30, 2025 | -$0.21 | +25.0% | -61.5% |
| Total Assets | September 30, 2025 | $129.86M | +13.3% | -10.4% |
| Cash and Equivalents | September 30, 2025 | $3.67M | -45.7% | -36.1% |
| Stockholders Equity | September 30, 2025 | $35.36M | +73.6% | -29.7% |
| R&D Expense | September 30, 2025 | $14.97M | -9.4% | -26.2% |
| Operating Income | September 30, 2025 | -$19.07M | +7.0% | +22.9% |
| Shares Outstanding | September 30, 2025 | 59.88M | +45.4% | +0.0% |
- Eledon Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2016.
- Eledon Pharmaceuticals, Inc. reported Net Income of -$45.62 million for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed a decrease of -26.1% in Net Income compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported Diluted EPS of $0.52 per share (loss) for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed an increase of +21.2% in Diluted EPS compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported Total Assets of $169.01 million for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed a decrease of -4.7% in Total Assets compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported Cash and Equivalents of $22.81 million for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed an increase of +11.0% in Cash and Equivalents compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported Stockholders Equity of $81.08 million for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed an increase of +29.8% in Stockholders Equity compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported R&D Expense of $66.27 million for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed an increase of +27.5% in R&D Expense compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported Operating Income of -$43.00 million for fiscal year 2023.
- Eledon Pharmaceuticals, Inc. showed an increase of +51.4% in Operating Income compared to the prior fiscal year.
- Eledon Pharmaceuticals, Inc. reported Shares Outstanding of 75.43 million shares for fiscal year 2025.
- Eledon Pharmaceuticals, Inc. showed an increase of +26.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: